Blueprint Medicines (BPMC) option implied volatility elevated into reporting data on its RET inhibitor BLU-667 at a cancer meeting
Get Alerts BPMC Hot Sheet
Join SI Premium – FREE
Blueprint Medicines (NASDAQ: BPMC) May call option implied volatility is at 127, June is at 77; compared to its 52-week range of 48 to 112 after reporting data on its RET inhibitor BLU-667 at a cancer meeting.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ishares Iboxx $ Investment Grade Corporate Bond Etf (LQD) option IV at low end of range
- ARK Innovation ETF (ARKK) call put ratio 1.5 calls to 1 put
- SPDR S&P 500 ETF Trust (SPY) option IV flat into Core PCE
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!